Gain Therapeutics, Inc. (GANX) is a publicly traded company in the Unknown sector. Across all available filings, 6 corporate insiders have executed 21 transactions totaling $24.6M, demonstrating a bullish sentiment with $24.6M in net insider flow. The most recent transaction on Aug 9, 2024 involved a purchase of 14,400 shares valued at $14.5K.
No significant insider buying has been recorded for GANX in the recent period.
No significant insider selling has been recorded for GANX in the recent period.
Based on recent SEC filings, insider sentiment for GANX is bullish with an Insider Alignment Score of 100/100 and a net flow of $24.6M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at Gain Therapeutics, Inc. (GANX) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 6 insiders are actively trading GANX stock, having executed 21 transactions in the past 90 days. The most active insider is Salvatore Calabrese (Executive), who has made 2 transactions totaling $24.3M.
Get notified when executives and directors at GANX file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Aug 9, 2024 | Mack Gene | Executive | Purchase | 14,400 | $1.01 | $14.5K | |
| Aug 9, 2024 | Islam Khalid | Executive | Purchase | 50,000 | $1.00 | $50.0K | |
| Mar 28, 2024 | Scott Riley Jeffrey | Executive | Purchase | 30,000 | $3.86 | $115.8K | |
| Mar 26, 2024 | Alder Matthias | Executive | Option Exercise | 637 | $N/A | $0 | |
| Mar 26, 2024 | Alder Matthias | Executive | Option Exercise | 18,750 | $N/A | $0 | |
| Mar 26, 2024 | Alder Matthias | Executive | Option Exercise | 825 | $N/A | $0 | |
| Mar 26, 2024 | Alder Matthias | Executive | Payment | 6,085 | $4.06 | $24.7K | |
| Dec 21, 2023 | Alder Matthias | Executive | Sale | 206 | $2.46 | $507 | |
| Dec 20, 2023 | Alder Matthias | Executive | Option Exercise | 637 | $N/A | $0 | |
| Dec 7, 2023 | Alder Matthias | Executive | Sale | 1,820 | $2.50 | $4.5K | |
| Oct 1, 2023 | Alder Matthias | Executive | Option Exercise | 825 | $N/A | $0 | |
| Sep 20, 2023 | Alder Matthias | Executive | Option Exercise | 2,550 | $N/A | $0 | |
| Sep 20, 2023 | I. Richman Eric | Executive | Option Exercise | 54,900 | $N/A | $0 | |
| Jul 1, 2023 | Alder Matthias | Executive | Option Exercise | 3,300 | $N/A | $0 | |
| May 25, 2022 | I. Richman Eric | Executive | Purchase | 2,482 | $2.58 | $6.4K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 9 | $24.6M | 99.7% |
Exercise(M) | 9 | $38.7K | 0.2% |
Payment(F) | 1 | $24.7K | 0.1% |
Sale(S) | 2 | $5.1K | 0.0% |
Insiders at Gain Therapeutics, Inc. are accumulating shares at an accelerated pace. With 6 insiders making 21 transactions totaling $24.6M in purchases versus $5.1K in sales, the net buying activity of $24.6M signals strong executive confidence. Salvatore Calabrese (Executive) leads the buying activity with $24.3M in transactions across all time.